NCT00411190View on ClinicalTrials.gov

Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 19, 2006

Primary Completion Date

December 15, 2006

Study Completion Date

December 15, 2006

Conditions
Osteoarthritis
Interventions
DRUG

Relacatib

Subjects will administer 60 or 120 mg tablets in Session 2

DRUG

Acetaminophen

Acetaminophen will be administered orally

DRUG

Ibuprofen

Ibuprofen will be administered orally

DRUG

Atorvastatin

Atorvastatin will be administered orally

Trial Locations (2)

2060

GSK Investigational Site, Antwerp

4000

GSK Investigational Site, Liège

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY